IQVIA and the Duke Clinical Research Institute (DCRI) have announced a strategic collaboration to improve the planning and execution of clinical studies focused on obesity and cardiometabolic diseases. The partnership combines IQVIA’s operational scale and technology with DCRI’s academic research expertise to provide coordinated, end-to-end trial support for sponsors, regulators, and patients. By aligning governance, data processes, and site execution early, the organizations aim to accelerate study timelines and strengthen submission readiness.
IQVIA’s Chief Medical and Scientific Officer, Jeffrey Spaeder, said, “Uniting our combined clinical strength and complementary capabilities enables us to maximize trial efficiency, accelerate timelines, and ultimately bring impactful therapies to patients faster.”
IQVIA has conducted more than 120 obesity trials enrolling over 90,000 patients and has supported development programs for every FDA-approved GLP-1 therapy to date. The collaboration will expand access to diverse patient populations across 56 countries and more than 3,000 research sites while integrating advanced analytics, electronic health records, and real-world data into study design.
Dr. Adrian Hernandez, Executive Director at DCRI, said, “Together with IQVIA, whose global scale and technology and AI capabilities enable efficient execution, we are expanding access to diverse patient populations and ensuring that our studies deliver meaningful results for sponsors, regulators, and most importantly, patients.” Both organizations expect the alliance to improve efficiency, enhance scientific rigor, and support faster delivery of therapies to patients.